Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers.

Breast cancer research and treatment - 1 Nov 2022

Nemati Shafaee Maryam, Goutsouliak Kristina, Lin Heather, Bevers Therese B, Gutierrez-Barrera Angelica, Bondy Melissa, Arun Banu

Abstract excerpt

BACKGROUND: Deleterious BRCA mutations confer a significant lifetime risk of breast cancer (BC) as well as contralateral BC (CBC) in patients who do not undergo prophylactic mastectomy. Prior reports have suggested that tamoxifen reduces the risk of CBC in BRCA mutation carriers. Whether aromatase inhibitors (AI) have the same effect is unknown. METHODS: This is a retrospective review of patients diagnosed with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aromatase Inhibitors
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Breast Neoplasms

Share to Mastectomy

Share to Mutation

Share to Tamoxifen

Source

Identifiers

PMID: 36006499
DOI: 10.1007/s10549-022-06688-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers.PMID 36006499Read ↗

Aromatase Inhibitors and Contralateral Breast Cancer in BRCA Mutation Carriers: A long-term Follow-upSemantic proximity Read ↗

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.Semantic proximity Read ↗

Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis.Semantic proximity Read ↗

Does bilateral mastectomy affect clinical outcomes in BRCA1/2 mutation carriers with primary breast cancer? A systematic review and meta-analysis.Semantic proximity Read ↗

Combined breast conservation therapy versus mastectomy for BRCA mutation carriers - A systematic review and meta-analysis.Semantic proximity Read ↗

Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.Semantic proximity Read ↗

Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation.Semantic proximity Read ↗

BRCA Mutation Testing in Determining Breast Cancer TherapySemantic proximity Read ↗

Differences Among a Modern Cohort of BRCA Mutation Carriers Choosing Bilateral Prophylactic Mastectomies Compared to Breast Surveillance.Semantic proximity Read ↗

Breast cancer surveillance following ovarian cancer in BRCA mutation carriers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.